已收盤 09-19 16:00:00 美东时间
-0.140
-4.12%
NeuroBo Pharmaceuticals press release (NASDAQ:NRBO): Q2 GAAP EPS of -$1.85. Cash was approximately $27.9 million as of June 30, 2024, compared to approximately $22.4 million as of December 31, 2023. M...
08-15 23:57
NeuroBo Pharmaceuticals (NASDAQ:NRBO) reported quarterly losses of $(1.85) per share which missed the analyst consensus estimate of $(1.12) by 65.18 percent. This is a 12233.33 percent decrease over losses of $(0.01) per
08-14 20:15
NeuroBo Pharmaceuticals: Part 2 of Phase 2a Trial of Da-1241 for Treatment of M...
08-14 20:03
NeuroBo Pharmaceuticals: Joint Research Agreement With Dong-a St & Immunofo...
08-14 20:03
NeuroBo Pharmaceuticals: Cash at End of Q2 Expected to Fund Co Into Q2 of 2025
08-14 20:02
NeuroBo Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provi...
08-14 20:01
NeuroBo Pharmaceuticals Completes Enrollment of the Sad Part 1 of Its Phase 1 C...
08-13 20:01
NeuroBo Pharmaceuticals Inc - Top Line Data From Sad Part 1 Expected Q3 2024
08-13 20:01
NeuroBo Pharmaceuticals: Top Line Data Readout From Mad Part 2 Expected in Q1 2...
08-13 20:01
新浪财经ESG评级中心提供包括资讯、报告、培训、咨询等在内的14项ESG服务,助力上市公司传播ESG理念,提升ESG可持续发展表现。点击查看【 ESG评级中...
08-12 07:01